Article

Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease.

Department of Emergency Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Academic Emergency Medicine (Impact Factor: 2.2). 06/2012; 19(6):664-72. DOI: 10.1111/j.1553-2712.2012.01364.x
Source: PubMed

ABSTRACT The objective was to identify clinical, social, and environmental risk factors for increased emergency department (ED) use in children with sickle cell disease (SCD).
This study was a secondary analysis of ED utilization data from the international multicenter Silent Cerebral Infarct Transfusion (SIT) trial. Between December 2004 and June 2010, baseline demographic, clinical, and laboratory data were collected from children with SCD participating in the trial. The primary outcome was the frequency of ED visits for pain. A secondary outcome was the frequency of ED visits for acute chest syndrome.
The sample included 985 children from the United States, Canada, England, and France, for a total of 2,955 patient-years of data. There were 0.74 ED visits for pain per patient-year. A past medical history of asthma was associated with an increased risk of ED utilization for both pain (rate ratio [RR] = 1.28, 95% confidence interval [CI] = 1.04 to 1.58) and acute chest syndrome (RR = 1.60, 95% CI = 1.03 to 2.49). Exposure to environmental tobacco smoke in the home was associated with 73% more ED visits for acute chest syndrome (RR = 1.73, 95% CI = 1.09 to 2.74). Each $10,000 increase in household income was associated with 5% fewer ED visits for pain (RR = 0.95, 95% CI = 0.91 to 1.00, p = 0.05). The association between low income and ED utilization was not significantly different in the United States versus countries with universal health care (p = 0.51).
Asthma and exposure to environmental tobacco smoke are potentially modifiable risk factors for greater ED use in children with SCD. Low income is associated with greater ED use for SCD pain in countries with and without universal health care.

Download full-text

Full-text

Available from: Jason J. Wang, Jul 04, 2015
1 Follower
 · 
107 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a common comorbid factor in sickle cell disease (SCD). However, the incidence of asthma in SCD is much higher than expected compared to rates in the general population. Whether "asthma" in SCD is purely related to genetic and environmental factors or rather is the consequence of the underlying hemolytic and inflammatory state is a topic of recent debate. Regardless of the etiology, hypoxemia induced by bronchoconstriction and inflammation associated with asthma exacerbations will contribute to a cycle of sickling and subsequent complications of SCD. Recent studies confirm that asthma predisposes to complications of SCD such as pain crises, acute chest syndrome, and stroke and is associated with increased mortality. Early recognition and aggressive standard of care management of asthma may prevent serious pulmonary complications and reduce mortality. However, data regarding the management of asthma in SCD is very limited. Clinical trials are needed to evaluate the effectiveness of current asthma therapy in patients with SCD and coincident asthma, while mechanistic studies are needed to delineate the underlying pathophysiology.
    11/2013; 2013:604140. DOI:10.1155/2013/604140
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE:: The burden of acute gastroenteritis (AGE) in U.S. children is substantial. Research into outpatient treatment strategies has been hampered by the lack of easily used and validated gastroenteritis severity scales relevant to the populations studied. We sought to evaluate, in a U.S. cohort, the reliability, construct validity and generalizability of a gastroenteritis severity scale previously derived in a Canadian population, the Modified Vesikari Score (MVS). METHODS:: We conducted a prospective, cohort, clinical observational study of children 3-48 months of age with AGE presenting to 5 U.S. emergency departments (EDs). A baseline MVS score was determined in the ED, and telephone follow-up 14 days after presentation was used to assign the follow-up MVS. We determined reliability using inter-item correlations; construct validity via principal component factor analysis; cross sectional construct validity via correlations with the presence of dehydration, hospitalization and day-care and parental work absenteeism, and generalizability via score distribution among sites. RESULTS:: 218/274 patients (80%) were successfully contacted for follow-up. Cronbach's alpha was 0.63 indicating expectedly low internal reliability, because of the multidimensional properties of the MVS. Factor analysis supported the appropriateness of retaining all variables in the score. Disease severity correlated with dehydration (P < 0.001), hospitalization (P < 0.001), and subsequent day care (P = 0.01) and work (P < 0.001) absenteeism. The MVS was normally distributed, and scores did not differ between sites. CONCLUSION:: The MVS effectively measures global severity of disease and performs similarly in varying populations within the U.S. health care system. Its characteristics support its use in multi-site outpatient clinical trials.
    Journal of pediatric gastroenterology and nutrition 05/2013; DOI:10.1097/MPG.0b013e31829ae5a3 · 2.87 Impact Factor